Xenetic Biosciences (NASDAQ:XBIO) Announces Earnings Results

Xenetic Biosciences (NASDAQ:XBIO) announced its earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.14), Zacks reports. Xenetic Biosciences had a negative return on equity of 47.21% and a negative net margin of 161.63%. The company had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million.

Xenetic Biosciences Stock Performance

Shares of NASDAQ:XBIO traded up $0.01 during trading on Thursday, hitting $3.66. The company’s stock had a trading volume of 15,791 shares, compared to its average volume of 11,249. Xenetic Biosciences has a fifty-two week low of $2.78 and a fifty-two week high of $5.20. The business has a 50 day moving average price of $3.89 and a two-hundred day moving average price of $3.93. The company has a market capitalization of $5.64 million, a PE ratio of -1.38 and a beta of 2.25.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a research report on Tuesday, August 20th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.